HepaRG™ is a reliable, robust and well published human hepatic cell line used in an ever-growing range of applications.
HepaRG™ has many key advantages, including:
Species: Human
Origin: Liver tumor of a patient suffering from hepatocarcinoma and hepatitis C infection.
Safety data: Absence of hepatitis B, hepatitis C and HIV1 viruses checked by PCR on the cell suspension.
Biosafety level: Level 2, as recommended in the CDC-NIH Manual, Biosafety in Microbiological and Biomedical Laboratories,5th edition, N°21-1112 Revised December 2009
CYP genotyping data: Obtained in collaboration with N. Picard at Limoges hospital (France) using a validated TaqMan allelic discrimination assay (ABI PRISM 7000 Sequence Detection System, Applied-Biosystems).
SNPs: Single Nucleotide Polymorphisms wt: wild-type mut: mutation **: wt=G T=minor allele in Caucasians
|
CYP2D6 | |
*2 (2850C>T) | *2/wt | |
*3 (2549delA) | wt/wt | |
*4 (1846G>A) | wt/wt | |
*7 (2935A>C) | wt/wt | |
*10 (100C>T) | wt/wt | |
CYP3A4 | ||
*1B (392G>A) | wt/wt | |
OATP1B1 (=OATP2) | ||
*5 (521T>C) | wt/*5 | |
OATP1B3 (=OATP8) | ||
334T>G | wt/wt** | |
MRP2 | ||
-24C>T | wt/wt | |
1249G>A | wt/mut | |
3972C>T | wt/mut |
When using growth-stage cells, a common question is whether they have stability and a useful life once they are differentiated, and with HepaRG™, the answer is "yes!". They can be grown and passaged 8 times when used according to our recommended protocols and medium supplements.
The differentiation process is the same across passages and cells are usable for at least 4 weeks once differentiation is achieved.
Biopredic International has complete User Instructions allowing for maximum quality of differentiated cells, which require non expensive materials for their use. HepaRG™ cells are actually more cost-effective compared with cryopreserved primary human hepatocytes.
Biopredic International has also developed media supplements for the production, culture, and assay-specific use of the HepaRG™ cell line for drug discovery and development, pharmacology and toxicology, biomarker research and related services.
HepaRG™ HPR101 undifferentiated cells are available
• under a Material Transfer Agreement for academic researchers
• through a Sublicense for researchers in commercial organisations.
HepaRG™ HPR116 and HPR116NS differentiated cells are available through a Limited Use License Agreement.
BIOPREDIC International | customersinquiries@biopredic.com | Phone: +33 (0)2 99 14 36 14 | Parc d'Affaires de la Bretèche 35760 Saint Grégoire FRANCE